 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 663 | 回復(fù): 0 | ||
caijing1986銅蟲 (初入文壇)
|
[求助]
專業(yè)翻譯英文摘要
|
|
Standard Versus Extended Duration DirectActing Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment Abstract Background: Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear whether extending therapy in slow responders affects outcomes. Objectives: The primary objective was to compare SVR rates between traditional and extended duration groups. Secondary objectives were to compare SVR rates among subgroups and to determine factors associated with SVR. Methods: This institutional review board–approved, retrospective, single-center study identified patients with chronic hepatitis C virus (HCV) infection with detectable week 4 HCV RNA who were treated with DAAs. Patients were excluded for early discontinuation, treatment regimen not recommended first-line, or missing HCV RNA labs. Patients were stratified into traditional and extended duration groups. The primary end point was SVR. Secondary end points included factors associated with SVR and rationale for extension of therapy duration. Results: A total of 363 patients were included; 58 (16%) received extended therapy. Patients were primarily genotype 1a (70%) and treatment naïve (80%). More than half had advanced fibrosis or cirrhosis. SVR12 rates were 100% in the extended duration group and 96.7% in the traditional duration group (P = 0.37). There were no associations with SVR and prespecified patient-specific factors. Sample size was limited. Conclusion and Relevance:Based on these findings, a recommendation for extension of therapy cannot be made for patients with detectable HCV RNA at week 4 of treatment at this time. Cost analyses may help guide recommendations to re-treat rare failures versus extend therapy in all slow responders. Keywords hepatitis C, response-guided therapy, direct-acting antivirals |
回復(fù)此樓» 猜你喜歡
085600 英一數(shù)二272求調(diào)劑
已經(jīng)有47人回復(fù)
-
材料328求調(diào)劑
已經(jīng)有6人回復(fù)
-
085600材料與化工（高分子）290分求調(diào)劑
已經(jīng)有3人回復(fù)
-
325求調(diào)劑
已經(jīng)有4人回復(fù)
-
320材料與化工，求調(diào)劑
已經(jīng)有4人回復(fù)
-
一志愿314求調(diào)劑
已經(jīng)有5人回復(fù)
-
求調(diào)劑
已經(jīng)有4人回復(fù)
-
347求調(diào)劑
已經(jīng)有4人回復(fù)
-
一志愿西交大材料學(xué)碩 346 求調(diào)劑
已經(jīng)有3人回復(fù)
-
304分材料專碩求調(diào)劑
已經(jīng)有8人回復(fù)
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 caijing1986 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 085600材料與化工（高分子）290分求調(diào)劑 +3 | wengyujian 2026-03-04 | 3/150 |
|
|---|---|---|---|---|
|
|
[考研] 能動297求調(diào)劑，本科川大 +3 | 邵11 2026-03-04 | 3/150 |
|
|
[考研] 295求調(diào)劑 +5 | 等春來， 2026-03-04 | 5/250 |
|
|
|
[考研] 266求調(diào)劑 +5 | 哇塞王帥 2026-03-03 | 5/250 |
|
|
|
[考研] 291求調(diào)劑 +4 | Afy123456 2026-03-03 | 7/350 |
|
|
|
[考研] 環(huán)境調(diào)劑 +8 | chenhanheng 2026-03-02 | 8/400 |
|
|
|
[考研] 理學(xué)，工學(xué)，農(nóng)學(xué)調(diào)劑，少走彎路，這里歡迎您！ +8 | likeihood 2026-03-02 | 11/550 |
|
|
|
[考研] 一志愿天津大學(xué)085600 319分 材料與化工 金屬方向 求調(diào)劑 +4 | 青科11 2026-03-02 | 4/200 |
|
|
|
[考研] 化學(xué)0703求調(diào)劑 學(xué)碩 理/工科均可 總分279 +3 | 1一11 2026-03-03 | 5/250 |
|
|
|
[考研] 288求調(diào)劑 +3 | 少71.8 2026-03-02 | 5/250 |
|
|
|
[考研] 275求調(diào)劑 +7 | 明遠(yuǎn)求學(xué) 2026-03-01 | 7/350 |
|
|
|
[考研] 一志愿山東大學(xué)材料與化工325求調(diào)劑 +5 | 半截的詩0927 2026-03-02 | 5/250 |
|
|
|
[考研] 291 求調(diào)劑 +3 | 化工2026屆畢業(yè)?/a> 2026-03-02 | 3/150 |
|
|
|
[考研] 265分求調(diào)劑不調(diào)專業(yè)和學(xué)校有行學(xué)上就 +6 | 禮堂丁真258 2026-02-28 | 9/450 |
|
|
|
[考研] 284求調(diào)劑 +10 | 天下熯 2026-02-28 | 11/550 |
|
|
|
[考研] 275求調(diào)劑 +3 | L-xin? 2026-03-01 | 6/300 |
|
|
|
[考研] 279求調(diào)劑 +3 | dua1 2026-03-01 | 4/200 |
|
|
|
[考研] 化工299分求調(diào)劑 一志愿985落榜 +5 | 嘻嘻(*^ω^*) 2026-03-01 | 5/250 |
|
|
|
[考研]
 尋找調(diào)劑
+4
|
LYidhsjabdj 2026-02-28 | 4/200 |
|
|
|
[高分子] 求環(huán)氧樹脂研發(fā)1名 +3 | 孫xc 2026-02-25 | 11/550 |
|